Overview

WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm. This study was amended to allow for a non-randomized arm and increased enrollment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boston Scientific Corporation
Treatments:
Warfarin